International Niemann–Pick Disease Alliance

Updates

  1. Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

    Orphazyme A/S Investor News                                                                       ...

    Read story
  2. Mallinckrodt Pharmaceuticals Statement: Adrabetadex for NPC-1

    Please take a moment to read this important announcement from Mallinckrodt Pharmaceuticals in regard to the clinical trial of Adrabetadex for NPC-1. We recognise that this may be a surprising and disappointing development for our community as a whole. ...

    Read story
  3. Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website

    GAINESVILLE, FL – (BusinessWire) – May 26, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, issued a press release...

    Read story
  4. Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    Top line results of Phase I study confirm favorable safety and tolerability of Trappsol® Cyclo™ in patients with NPC1 and demonstrate biological responses for both dose groups. An Unblinded Interim Analysis of Phase I/II study shows encouraging signals in...

    Read story
  5. Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

    GAINESVILLE, FL – (BusinessWire) – May 19, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it...

    Read story
  6. Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    GAINESVILLE, FL – (Businesswire) – May 18, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrinbased products for the treatment of Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Disease, today announced that it received...

    Read story
  7. Cyclo Therapeutics Closes $2.0 Million Private Placement

    ALACHUA, FL – (BusinessWire) – April 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it...

    Read story
  8. A message from Orphazyme to the global community of patients, family members and healthcare providers impacted by the corona virus pandemic (COVID-19):

    March 2020 A message from Orphazyme to the global community of patients, family members and healthcare providers impacted by the corona virus pandemic (COVID-19): This is an uncertain and difficult time for us all. As we face these challenges,...

    Read story
  9. IntraBio Receives FDA Fast Track Designation for Niemann-Pick Disease

    OXFORD, UK / ACCESSWIRE / March 25, 2020 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead compound (IB1001) for the treatment of Niemann-Pick...

    Read story
  10. Cyclo Therapeutics Inc. Announces Positive Safety Profile of its Drug Trappsol® Cyclo™ in the Treatment of Niemann Pick Disease Type C

    GAINESVILLE, FL – (Businesswire) – March 23, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the Safety...

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

Think Again. Think NP-C

Join our international campaign to improve diagnosis of NP-C!